BCAB BioAtla, Inc.
Financings ·
BioAtla can sell up to $40.0 million of stock to Yorkville over 36 months, but its cash was $1.5 million at June 30, 2026, and its prior $15.0 million line raised about $0.4 million.
A Nasdaq hearing panel let BioAtla stay listed on conditions: a transfer to the Nasdaq Capital Market by September 26, 2025, equity compliance by December 31, 2025 and bid price compliance by February 2, 2026.
BioAtla is selling 9,679,158 shares with warrants at a combined $0.9520 each, through sole placement agent Tungsten Advisors, for about $9.2 million gross and about $8.5 million net.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $43.6 million | $63.1 million |
| Net income (loss) | -$59.6 million | -$69.8 million |
| Cash from operations | -$48.2 million | -$71.9 million |
| Cash and equivalents | $7.1 million | $49.0 million |
Our latest story on this, dated Dec 20, 2024: "BioAtla agrees to about $9.2 million registered direct offering at $0.9520". The story links the filing or release it is based on. Read the story.
BioAtla, Inc. trades under the ticker BCAB on OTC.
BioAtla, Inc. is listed on OTC.
The SEC Central Index Key (CIK) for BioAtla, Inc. is 1826892. Its filings are on SEC EDGAR.
32,315,301 shares as of 2021-08-13, per the cover page of its 10-Q filed 2021-08-13.
Our directory records BioAtla, Inc. under United States.
Our directory classifies BioAtla, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for BioAtla, Inc. is US09077B2034.
aibio.space lists BioAtla, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
BioAtla, Inc. reported a net loss of $59.6 million for the fiscal year ended Dec 31, 2025, and used $48.2 million of cash in operations, per its annual report to the SEC.
$43.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
$1.5 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on BioAtla, dated Oct 20, 2026: "BioAtla signs $40.0 million standby equity deal with Yorkville". BioAtla can sell up to $40.0 million of stock to Yorkville over 36 months, but its cash was $1.5 million at June 30, 2026, and its prior $15.0 million line raised about $0.4 million. Source.
From our story of Sep 22, 2025: The 8-K's forward-looking statements list factors that raise substantial doubt about the company's ability to continue as a going concern, along with the need for additional funding to continue development of its CAB technology platform and product candidates. Source.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,7.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,5.02,7.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,7.01,8.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form PREM14A. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.02,5.03,5.07,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio